ScienceMed®

Efficacy of combination therapy with mometasone and montelukast versus mometasone alone in treatment of adenoid hypertrophy in children: A systematic review and meta-analysis

Otorrinolaringologia
Imagem de arquivo, ilustrativa — não é do estudo. Radiografia da mão de uma criança de 4 anos (Viena, 1896). Josef Maria Eder e Eduard Valenta · CC0 · Wikimedia Commons

MetanáliseNível 1 · Evidência consolidadaAmerican journal of otolaryngology19 dez 20246 citações

Salvar

Resumo original em inglês

O que aconteceu

Intranasal mometasone and oral montelukast have been found to be effective for adenoid hypertrophy in children. We aimed to compare the efficacy of combination therapy of mometasone and montelukast versus mometasone alone for adenoid hypertrophy in children.

Following PRISMA guidelines, we systematically searched PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov databases for randomized controlled trials (RCTs) comparing combination therapy of mometasone and montelukast with mometasone alone for adenoid hypertrophy in children. The outcomes of interest were rhinorrhea, snoring, mouth breathing, and adenoid/nasopharynx ratio. Data were pooled using a random effects model to generate mean differences (MD).

O que encontraram

3 RCTs comprising a total of 207 patients were included; (combination therapy n = 104 (50.2 %). Rhinorrhea (MD -1.47; 95 % CI -1.85 to -1.09; p < 0.01; I2 = 0 %), snoring (MD -1.33; 95 % CI -1.65 to -1.00; p < 0.01; I2 = 0 %), and mouth breathing (MD -1.06; 95 % CI -1.40 to -0.71; p < 0.01; I2 = 0 %) were significantly lower in patients treated with combination therapy. No difference was observed in the adenoid/nasopharynx ratio between the groups. However, analysis excluding the study with a high risk of bias showed a significant reduction in the adenoid/nasopharynx ratio (MD -10.73; 95 % CI -13.56 to -7.90; p < 0.01; I2 = 0 %) in the combination therapy group. During the 3-month follow-up period after cessation of treatment, adenoid/nasopharynx ratio, rhinorrhea, snoring, and mouth breathing were significantly lower in the combination therapy group.

Por que isso importa

In children with adenoid hypertrophy, combination therapy reduced rhinorrhea, snoring, mouth breathing, and adenoid/nasopharynx ratio at the end of the treatment period and 3 months after treatment cessation.

Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.

O estudo original

Efficacy of combination therapy with mometasone and montelukast versus mometasone alone in treatment of adenoid hypertrophy in children: A systematic review and meta-analysis

Meghna Joseph, Mrinal Murali Krishna, Ancy Jenil Franco, Laura Jekov, Renan Yuji Ura Sudo, Thamiris Dias Delfino Cabral

Descritores MeSH

  • Acetates
  • Adenoids
  • Quinolines
  • Sulfides
  • Mometasone Furoate
  • Female
  • Humans
  • Hypertrophy
  • Male
  • Treatment Outcome

Veja também

Estudos relacionados